本文選題：人視網(wǎng)膜色素上皮細(xì)胞 + 人臍靜脈內(nèi)皮細(xì)胞　； 參考：《昆明醫(yī)科大學(xué)》2016年博士論文

【摘要】：目的通過體外實驗研究探討非諾貝特對人視網(wǎng)膜色素上皮細(xì)胞(RPE)和人臍靜脈內(nèi)皮細(xì)胞(HUVEC)活力的影響及可能的機制,通過體內(nèi)實驗探討激光誘導(dǎo)BN大鼠脈絡(luò)膜新生血管形成過程中脈絡(luò)膜和視網(wǎng)膜內(nèi)VEGFC和VEGFR-3的表達(dá)變化規(guī)律及非諾貝特對脈絡(luò)膜新生血管發(fā)生發(fā)展的影響作用,為眼脈絡(luò)膜新生血管性相關(guān)疾病提供新的思路。方法1.將RPE和HUVEC細(xì)胞分組：RPE正常組,RPE+非諾貝特組,RPE缺氧組,RPE缺氧+非諾貝特組；HUVEC細(xì)胞正常組,]HUVEC+缺氧上清組；將健康成年BN大鼠隨機分成空白對照組和實驗組,實驗組分為非諾貝特干預(yù)組(用藥組),非干預(yù)組(實驗對照組),每組以1w、2w、3w和4w為觀察點。2.用超氧化物陰離子探針檢測RPE缺氧情況,MTT檢測細(xì)胞活力,ELISA檢測RPE細(xì)胞培養(yǎng)液上清中VEGFC和VEGFR-3的表達(dá)；細(xì)胞劃痕實驗檢測細(xì)胞遷移能力,細(xì)胞管腔形成實驗檢測]HUVEC細(xì)胞的血管形成能力,qRT-PCR和Western-blot檢測RPE細(xì)胞VEGFC和VEGFR-3的mRNA和蛋白質(zhì)的表達(dá)水平；用FFA檢測非諾貝特干預(yù)組和非干預(yù)組激光斑處不同時間點脈絡(luò)膜新生血管的滲漏面積和滲漏強度,用凝聚素B4染脈絡(luò)膜鋪片觀察激光斑處不同時間點新生血管內(nèi)皮細(xì)胞的染色程度,行BN大鼠眼球冰凍切片,用免疫熒光化學(xué)檢測激光斑處脈絡(luò)膜和視網(wǎng)膜VEGFC和VEGFR-3的分布情況,用qRT-PCR技術(shù)定量檢測不同時間點各組脈絡(luò)膜和視網(wǎng)膜內(nèi)VEGFC和VEGFR-3的mRNA表達(dá)變化,用Western Blot技術(shù),檢測不同時間點各組脈絡(luò)膜和視網(wǎng)膜內(nèi)VEGFC和VEGFR-3的蛋白質(zhì)表達(dá)變化。結(jié)果1.非諾貝特能抑制因缺氧引起的RPE細(xì)胞內(nèi)和培養(yǎng)液上清中VEGFC和VEGFR-3表達(dá)上調(diào)；2.缺氧培養(yǎng)RPE細(xì)胞上清液可促進(jìn)HUVEC細(xì)胞活力增加,細(xì)胞遷移數(shù)增多,管腔形成數(shù)增多,而非諾貝特能抑制這一過程；3.激光誘導(dǎo)BN大鼠脈絡(luò)膜新生血管形成后,脈絡(luò)膜和視網(wǎng)膜內(nèi)均可以發(fā)現(xiàn)有VEGFC和VEGFR-3的表達(dá),其中VEGFC主要表達(dá)于激光斑上方視網(wǎng)膜神經(jīng)節(jié)細(xì)胞層內(nèi),VEGFR-3主要表達(dá)與脈絡(luò)膜激光斑處的新生血管區(qū)域,正常的脈絡(luò)膜和視網(wǎng)膜未發(fā)現(xiàn)有上訴兩種因子的表達(dá)；4.激光誘導(dǎo)BN大鼠脈絡(luò)膜新生血管形成后,脈絡(luò)膜和視網(wǎng)膜表達(dá)的VEGFC和VEGFR-3呈現(xiàn)一定的規(guī)律性,在脈絡(luò)膜和視網(wǎng)膜中VEGFC表達(dá)隨時間的推移呈現(xiàn)逐漸下調(diào)的趨勢,在脈絡(luò)膜中VEGFR-3的表達(dá)呈現(xiàn)逐漸升高并持續(xù)維持于高表達(dá)水平,在視網(wǎng)膜中VEGFR-3基本不表達(dá)或僅有少量表達(dá)；5.非諾貝特能夠明顯下調(diào)激光誘導(dǎo)BN大鼠脈絡(luò)膜新生血管形成和發(fā)展過程,其能夠明顯下調(diào)視網(wǎng)膜和脈絡(luò)膜內(nèi)VEGFC的表達(dá)量,脈絡(luò)膜內(nèi)的VEGFR-3的表達(dá)下調(diào)與非諾貝特下調(diào)VEGFC的表達(dá)量有關(guān)。結(jié)論1.CoCl2誘導(dǎo)體外培養(yǎng)的RPE細(xì)胞缺氧導(dǎo)致VEGFC和VEGFR-3表達(dá)上調(diào),非諾貝特能夠抑制RPE細(xì)胞缺氧狀態(tài)下VEGFC和VEGFR-3的表達(dá)上調(diào)；2.RPE缺氧后的細(xì)胞培養(yǎng)上清液中的VEGFC和VEGFR-3濃度上升,上清液對HUVEC細(xì)胞具有促增殖、遷移和毛細(xì)血管成管活性的作用,提示RPE細(xì)胞在缺氧導(dǎo)致的CNV形成過程中起到了重要的作用,非諾貝特能夠抑制RPE細(xì)胞缺氧后的VEGFC和VEGFR-3的上調(diào),從而有可能通過調(diào)節(jié)RPE的功能活性來間接影響HUVEC細(xì)胞的活性從而達(dá)到抑制新生血管的形成。3.VEGFC主要表達(dá)于BN大鼠激光損傷區(qū)域上方的視網(wǎng)膜神經(jīng)節(jié)細(xì)胞層內(nèi),VEGFR-3主要表達(dá)于激光斑處的脈絡(luò)膜損傷區(qū)；4.非諾貝特能夠下調(diào)脈絡(luò)膜和視網(wǎng)膜內(nèi)VEGFC的表達(dá),對脈絡(luò)膜內(nèi)VEGFR-3的下調(diào)作用可能是通過VEGFC的間接影響。
[Abstract]:Objective to investigate the effects and possible mechanisms of fenofibrate on human retinal pigment epithelial cells (RPE) and human umbilical vein endothelial cells (HUVEC) in vitro, and to explore the changes in the expression of VEGFC and VEGFR-3 in choroidal and retina during the formation of choroidal neovascularization in BN rats by in vivo experiments. The effects of fenofibrate on the development of choroidal neovascularization, provide new ideas for the choroidal neovascularization related diseases. Methods 1. RPE and HUVEC cells were divided into RPE normal group, RPE+ fenofibrate group, RPE anoxic group, RPE anoxic + fenofibrate group, normal HUVEC cell group,]HUVEC+ hypoxia supernatant group, and healthy adult BN Rats were randomly divided into blank control group and experimental group. The experimental group was divided into Fenofibrate Intervention group (drug group), non intervention group (experimental control group), 1W, 2W, 3W and 4W were used as observation points for the detection of RPE anoxia with superoxide anion probe.2., MTT detection of cell viability, ELISA detected VEGFC and VEGFR-3 expression in the supernatant of RPE cell culture liquid. The cell migration ability was detected by cell scratch test, the angiogenesis ability of]HUVEC cells was detected by cell lumen formation, and the expression level of mRNA and protein of VEGFC and VEGFR-3 in RPE cells was detected by qRT-PCR and Western-blot, and the choroidal neovascularization at different time points at different spots in the fenofibrate and non intervention groups was detected with FFA. The coloring degree of the neovascular endothelial cells at different time points at the laser spot was observed with the leaking area and the leakage intensity. The frozen section of the eye of the BN rat was frozen. The distribution of VEGFC and VEGFR-3 in the choroid and retina at the laser spot was detected by immunofluorescence chemistry, and the different time points were measured by qRT-PCR technique. The changes in mRNA expression of VEGFC and VEGFR-3 in choroid and retina. Western Blot technique was used to detect the changes in the protein expression of VEGFC and VEGFR-3 in the choroid and retina at different time points. Results 1. fenofibrate could inhibit the up-regulated expression of VEGFC and VEGFR-3 in the RPE cells and the culture liquid supernatant caused by hypoxia; 2. anoxic culture. The supernatant of RPE cells could increase the vitality of HUVEC cells, increase the number of cell migration, increase the number of cavity formation, and fenofibrate can inhibit this process. 3. after the formation of choroidal neovascularization in BN rats, the expression of VEGFC and VEGFR-3 can be found in the choroid and retina, and VEGFC is mainly expressed above the laser spot. In the retinal ganglion cell layer, VEGFR-3 is mainly expressed in the neovascular region of the choroidal laser spot, and the expression of two factors is not found in the normal choroid and retina. 4. after the formation of the choroidal neovascularization in the BN rats, the VEGFC and VEGFR-3 in the choroid and retina present certain regularity, in the vein. The expression of VEGFC in the retinal membrane and retina gradually decreased with time. The expression of VEGFR-3 in the choroid gradually increased and maintained at the high expression level. In the retina, VEGFR-3 was basically not expressed or only a small amount of expression was expressed. 5. fenofibrate can obviously lower the laser induced choroidal neovascularization in BN rats. It can obviously reduce the expression of VEGFC in the retina and choroid, and the downregulation of VEGFR-3 in the choroid is related to the expression of fenofibrate down regulation of VEGFC. Conclusion 1.CoCl2 induced hypoxia in RPE cells in vitro leads to the up regulation of VEGFC and VEGFR-3 expression, and fenofibrate can inhibit VEGF under the hypoxia state of RPE cells. The expression of C and VEGFR-3 was up-regulated, and the concentration of VEGFC and VEGFR-3 in the supernatant of cell culture after 2.RPE hypoxia increased, and the supernatant had the role of promoting proliferation, migration and capillary formation of HUVEC cells, suggesting that RPE cells played an important role in the formation of CNV caused by hypoxia, and fenofibrate could inhibit the hypoxia of RPE cells. After the up regulation of VEGFC and VEGFR-3, it is possible to indirectly influence the activity of RPE to indirectly affect the activity of HUVEC cells to inhibit the formation of the neovascularization, which is mainly expressed in the retinal ganglion cell layer above the laser injured region of the BN rat, and VEGFR-3 is mainly expressed in the choroidal damage area at the laser spot; 4. Fenofibrate can downregulate the expression of VEGFC in the choroid and retina, and the down-regulation of VEGFR-3 in choroid may be indirectly mediated by VEGFC.

【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2016
【分類號】：R-332;R773.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 Toshiyuki Nakayama;Yang Cheul Cho;Yuka Mine;Ayumi Yoshizaki;Shinji Naito;Ichiro Sekine;;Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors,leiomyomas and schwannomas[J];World Journal of Gastroenterology;2006年38期

2 葛曉利,高平進(jìn);VEGFR-1與心血管疾病[J];中國微循環(huán);2005年03期

3 李軍;洪梅;潘鐵成;;Clinical Significance of VEGF-C and VEGFR-3 Expression in Non-small Cell Lung Cancer[J];華中科技大學(xué)學(xué)報(醫(yī)學(xué)英德文版);2006年05期

4 曲行舟;王麗珍;胡永杰;張陳平;;VEGFR3在不同臨床分期舌癌癌周淋巴管中的表達(dá)[J];口腔頜面外科雜志;2007年02期

5 ;Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX[J];World Journal of Gastroenterology;2010年17期

6 張雄;張紅梅;李昱;米粲;;Expressions of Beta-Catenin,SUFU and VEGFR-2 Proteins in Medulloblastoma[J];Chinese Journal of Cancer Research;2007年04期

7 陸樹健;于大海;閆紅;李晶;羅婷婷;卿海云;;新VEGFR2靶向抑制劑篩選及其抗腫瘤生物學(xué)活性檢測[J];中國臨床新醫(yī)學(xué);2013年12期

8 馬惠文,梁后杰;VEGFR-3在食管鱗癌中的表達(dá)及與新生淋巴管形成的關(guān)系[J];第三軍醫(yī)大學(xué)學(xué)報;2004年17期

9 賈如江;侯麗艷;張有成;呂志誠;;VEGFR-3 siRNA體外對人結(jié)腸癌細(xì)胞生長的抑制作用[J];世界華人消化雜志;2008年16期

10 王曉飛;;下調(diào)VEGFR-1基因表達(dá)對抑制乳腺癌細(xì)胞增殖的影響[J];臨床醫(yī)學(xué)工程;2010年06期

相關(guān)會議論文 前10條

1 ;Expression and biological function of vascular endothelial growth factor receptors in normal human and psoriatic epidermal keratinocytes[A];中華醫(yī)學(xué)會第十五次全國皮膚性病學(xué)術(shù)會議論文集[C];2009年

2 黃定德;李前偉;馮世斌;;基于VEGFR靶點的高親和力多肽的篩選及鑒定[A];中華醫(yī)學(xué)會第九次全國核醫(yī)學(xué)學(xué)術(shù)會議論文摘要匯編[C];2011年

3 王明明;張曉;李泉;田潤華;葛銀林;;敲減VEGFR-1基因抑制乳腺癌細(xì)胞增殖的研究[A];華東六省一市生物化學(xué)與分子生物學(xué)會2008年學(xué)術(shù)交流會論文摘要匯編[C];2008年

4 左朝暉;李官成;胡錦躍;謝平麗;李躍輝;周國華;;骨髓中表達(dá)VEGFR-1的造血前體干細(xì)胞啟動了膽囊癌淋巴結(jié)預(yù)轉(zhuǎn)移及臨床意義[A];中國抗癌協(xié)會膽道腫瘤專業(yè)委員會成立大會暨第一屆全國膽道腫瘤學(xué)術(shù)會議論文集[C];2009年

5 吳賢杰;;VEGFR-2在非內(nèi)皮來源細(xì)胞上表達(dá)的研究進(jìn)展(綜述)[A];2012年浙江省皮膚病性病學(xué)術(shù)會議論文集[C];2012年

6 蘇葉翔;徐丹;成宜娟;尤啟冬;孫麗萍;;基于雜環(huán)并嘧啶類VEGFR-2抑制劑的設(shè)計及合成方法學(xué)研究[A];2012長三角藥物化學(xué)研討會論文集[C];2012年

7 劉斌;趙怡芳;張文峰;;口腔頜面部淋巴管畸形的VEGF-C和VEGFR-3表達(dá)[A];2002全國口腔頜面部血管瘤治療與研究學(xué)術(shù)研討會論文匯編[C];2002年

8 郭海霞;李文益;薛紅漫;黎陽;夏焱;徐令;;慢病毒載體攜帶的VEGFR_2 sRNA對HL60的抑制作用[A];中華醫(yī)學(xué)會第十四次全國兒科學(xué)術(shù)會議論文匯編[C];2006年

9 陶蓓蓓;劉姝媛;張彩彩;付偉;蔡文杰;王益;沈慶;王銘潔;陳瑩;張利佳;朱依諄;朱依純;;H2S促血管新生的機制研究——H2S“受體”VEGFR2的發(fā)現(xiàn)[A];中國生理學(xué)會張錫鈞基金第十二屆全國青年優(yōu)秀生理學(xué)學(xué)術(shù)論文交流及評獎會議綜合摘要[C];2013年

10 王熙才;劉馨;陳艷;金從國;陳曉群;黃尤光;周永春;;口服型VEGFR-3 DNA疫苗在抑制肺癌中的作用[A];第十六屆中國科協(xié)年會——分3環(huán)境污染及職業(yè)暴露與人類癌癥學(xué)術(shù)研討會論文集[C];2014年

相關(guān)博士學(xué)位論文 前10條

1 趙文娟;氧濃度對人內(nèi)皮祖細(xì)胞VEGFR-1、VEGFR-2和CXCR4受體表達(dá)調(diào)控的研究[D];山東大學(xué);2015年

2 高國銳;激酶PI3K和VEGFR-2抑制劑的設(shè)計合成及生物活性研究[D];華東理工大學(xué);2015年

3 張祿卿;血管內(nèi)皮細(xì)胞生長因子受體-3在血管新生與淋巴管新生中的不同機制研究[D];南京大學(xué);2011年

4 趙劍峰;非諾貝特對人RPE細(xì)胞及BN大鼠CNV模型VEGF-C和VEGFR-3表達(dá)變化影響的體內(nèi)、體外實驗研究[D];昆明醫(yī)科大學(xué);2016年

5 艾軍華;VEGFR-1活化誘導(dǎo)上皮—間質(zhì)表型轉(zhuǎn)化促進(jìn)肝細(xì)胞癌侵襲轉(zhuǎn)移的研究[D];第三軍醫(yī)大學(xué);2008年

6 魏春山;葉下珠及其復(fù)方對HBx介導(dǎo)肝癌VEGFR3表達(dá)的影響[D];廣州中醫(yī)藥大學(xué);2012年

7 石小燕;VEGF-C及其受體VEGFR-3/Flt-4與腫瘤淋巴管生成、增殖及轉(zhuǎn)移關(guān)系的研究[D];華中科技大學(xué);2006年

8 王玲;HLECs分離培養(yǎng)及VEGFR-3結(jié)合肽靶向卵巢癌新生淋巴管分子顯像的實驗研究[D];第三軍醫(yī)大學(xué);2009年

9 伍星;靶向VEGFR2超聲分子顯像小鼠H22移植瘤實驗研究[D];重慶醫(yī)科大學(xué);2009年

10 范良生;靶向VEGFR-3的多肽TMTP2在惡性腫瘤靶向治療中的應(yīng)用研究[D];華中科技大學(xué);2012年

相關(guān)碩士學(xué)位論文 前10條

1 蘇婷婷;基于識別血管內(nèi)皮生長因子受體2（VEGFR2）的腫瘤靶向治療研究[D];西南大學(xué);2015年

2 章偉慧;PKGⅡ?qū)ξ赴┘?xì)胞VEGFR2介導(dǎo)的信號轉(zhuǎn)導(dǎo)通路的影響及分子機制[D];江蘇大學(xué);2016年

3 呂梅;血清淀粉樣蛋白A對VEGFR2的表達(dá)及血管新生影響的研究[D];山東大學(xué);2016年

4 余楊瀟;新型芳基脲類VEGFR抑制劑的設(shè)計、合成及抗腫瘤活性研究[D];廣西醫(yī)科大學(xué);2016年

5 張瑋;文昌魚VEGF與VEGFR的時空表達(dá)與功能初探[D];中國海洋大學(xué);2012年

6 王定平;VEGFR1陽性造血祖細(xì)胞在大腸癌肝轉(zhuǎn)移中的作用[D];瀘州醫(yī)學(xué)院;2012年

7 李鋼;新疆多民族食管鱗癌VEGFR-2與臨床病理生物學(xué)關(guān)系的研究[D];新疆醫(yī)科大學(xué);2015年

8 胡偉偉;VEGFR-Fc在DG44細(xì)胞中的表達(dá)及其生物活性檢測[D];安徽大學(xué);2013年

9 黃大偉;VEGFR_2siRNA腺病毒載體的構(gòu)建及其對腫瘤血管生成的影響[D];第四軍醫(yī)大學(xué);2005年

10 付春茂;弱激光照射對兔正畸牙周組織中VEGF受體VEGFR-2（VEGFR-2/KDR）表達(dá)影響的研究[D];吉林大學(xué);2005年

，

本文編號：1852172